Publications & Presentations
Rademikibart - Respiratory
Rapid and Sustained FEV1 improvements with Rademikibart in Type 2 Asthma: Impact of Eosinophils and FeNO
Presented at the 2025 European Respiratory Society (ERS) Congress, September 27 to Oct 1, 2025
Rademikibart in Moderate-to-Severe Asthma: Impact of Eosinophils and Regional Differences on Response
Presented at the 2025 European Respiratory Society (ERS) Congress, September 27 to Oct 1, 2025
Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic-driven Type 2 Asthma
Presented at the 2025 European Association of Allergy and Clinical Immunology (EAACI) Congress, June 13 to 16, 2025
Optimized Second-generation IL-4Rα Inhibition: Structural and Molecular Dynamics Properties of the Rademikibart Fab-IL-4Rα Complex
Presented at the American Thoracic Society (ATS) Congress, May 16-21, 2025
Effect of Rademikibart on Blood Eosinophil Counts in Patients with Asthma: Is there an IL-4Rα Class Effect?
Presented at the American Thoracic Society (ATS) Congress, May 16-21, 2025
Rapid Improvement in Lung Function Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
Presented at the American Thoracic Society (ATS) Congress, May 16-21, 2025
Efficacy of Rademikibart in COPD-like Patients: Sub-analyses from the Phase 2b Trial in Patients with Moderate-to-Severe Asthma
Presented at the American Thoracic Society (ATS) Congress, May 16-21, 2025
Improved lung function and asthma control observed with rademikibart in patients with moderate-to-severe asthma
Oral presentation at the European Respiratory Society (ERS) Congress, September 7-11, 2024
Rademikibart - Dermatology
Optimized Second-Generation IL-4Rα Inhibition: Structural and Molecular Dynamics Properties of Rademikibart Fab-IL-4Rα Complex
Presented at the 44th Annual Fall Clinical (FC) Dermatology Conference, October 24-27, 2024
Continued Improvement of Investigator and Patient Reported Outcomes into the 52-Week Maintenance Period were Observed with Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis (SEASIDE CHINA)
Presented at the European Academy of Dermatology and Venereology Congress (EADV), September 25-28, 2024
Eczema Area and Severity Index (EASI) scores improved, and encouraging safety and tolerability were observed, across 16 weeks of treatment with rademikibart (CBP-201) for moderate-to-severe atopic dermatitis (AD) A pivotal trial in China (CBP-201-CN002)
Presented at the World Congress of Dermatology (WCD), July 3-8, 2023
Improvements in investigator-rated outcomes across 16 weeks of treatment with rademikibart (CBP-201) for moderate-to-severe atopic dermatitis (AD): Results from a pivotal trial in China (CBP-201-CN002)
Presented at the World Congress of Dermatology (WCD), July 3-8, 2023
CBP-201, a next-generation IL-4Rα antibody, achieved all primary and secondary efficacy endpoints in the treatment of adults with moderate-to-severe atopic dermatitis (AD): A randomized, double-blind, pivotal trial in China (CBP-201-CN002)
Presented at the American Academy of Dermatology (AAD) Annual Meeting, March 17-21, 2023
The Effect of Baseline Disease Characteristics on Efficacy Outcomes: Results from a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial of CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis (AD)
Presented at the Maui Derm Conference, January 24, 2022
A randomized, double-blind, placebo-controlled, multiple ascending dose study of the safety, pharmacokinetics and preliminary efficacy of CBP-201 in adult patients with moderate to severe atopic dermatitis (CPB-201AU002)
Presented at the 29th European Academy of Dermatology and Venereology Congress (EADV), October 29, 2020
Icanbelimod – Ulcerative Colitis (UC)
The Effect of Baseline Disease Characteristics on Efficacy Outcomes: Results from a Phase 2b, Randomized, Double-Efficacy and safety of icanbelimod (CBP-307) in adults with moderate-to-severe ulcerative colitis: A phase 2, randomized, double-blind, placebo-controlled trial, Placebo-controlled Trial of CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis (AD)
Presented at the Advances in Inflammatory Bowel Diseases, December 14-16, 2023